+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Afinitor 2018 U.S. Promotional Audit Report

  • ID: 4615805
  • Report
  • Region: United States
  • 31 pages
  • MD Details
1 of 3

FEATURED COMPANIES

The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Afinitor through reportable promotional activity in 2018 and how does this compare to its peer set in the Astrocytoma, Breast Cancer, Neuroendocrine Tumors, and Renal Cancer markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Novartis's depth of coverage vary within key specialties (e.g., Hematology/Oncology, Neurology, Medical Oncology, Urology, Internal Medicine, Nephrology, and Radiation Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Afinitor throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Afinitor in 2018?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 8,400 paid interactions across 3,600 physicians made on behalf of Afinitor were carefully examined to support our analysis. In addition, interaction data from 25 peer products (i.e. Abraxane, Avastin, Bavencio, Cabometyx, Fareston, Faslodex, Halaven, Herceptin, Ibrance, Inlyta, Ixempra, Kadcyla, Kisqali, Lenvima, Lutathera, Lynparza, Nerlynx, Nexavar, Opdivo, Perjeta, Somatuline Depot, Sutent, Talzenna, Verzenio, and Votrient) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

Overview:
  • Introduction
  • Sunshine Act and Open Payments Data
  • Transfer of Value
  • Author's Platform
Afinitor - Peer Set:
  • Afinitor Peer Set Selection
Afinitor - Promotional Benchmarking:
  • Chart 1 Total Number of Physicians Reached by Specialty Type
  • Chart 2 Distribution of Physicians Reached by Specialty Type
  • Chart 3 Total Number of Payments by Type
  • Chart 4 Distribution of Payments by Type
  • Chart 5 Total Number of Payments / Week
  • Chart 6 Payment Value by Type
Afinitor - Physician Coverage by Geography:
  • Chart 7 Hematology/Oncology
  • Chart 8 Neurology
  • Chart 9 Medical Oncology
  • Chart 10 Urology
  • Chart 11 Internal Medicine
  • Chart 12 Nephrology
  • Chart 13 Radiation Oncology
Afinitor - Meal Frequency:
  • Chart 14 Hematology/Oncology
  • Chart 15 Neurology
  • Chart 16 Medical Oncology
  • Chart 17 Urology
  • Chart 18 Internal Medicine
  • Chart 19 Nephrology
  • Chart 20 Radiation Oncology
Afinitor - Most Engaged Physicians:
  • Table 1: Top Physicians (By Total Number of Meals) in 2018
  • Table 2: Top Speakers (By Total Number of Speaking Events) in 2018
About:
  • Background
  • Service Lines
  • Contact
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll